title: [Intravitreal bevacizumab in neovascularisation secondary to age-related macular degeneration].
authors.forename: L
authors.initials: L
authors.lastname: Ordóñez Fernández
authors.forename: M L
authors.initials: ML
authors.lastname: Celemín Viñuela
authors.forename: C
authors.initials: C
authors.lastname: Fernández Lisa
authors.forename: A
authors.initials: A
authors.lastname: García Alonso
authors.forename: M
authors.initials: M
authors.lastname: Fonolla Gil
authors.forename: E
authors.initials: E
authors.lastname: Fernández Bustillo
mesh_terms: D000367:Age Factors; D000368:Aged; D000375:Aging / Q000502:physiology*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab